Therapeutic drug monitoring (TDM) is the quantification and interpretation of drug
concentrations in blood to optimize pharmacotherapy. It considers the interindividual …

Cytochrome P450 2D6 (CYP2D6) is a critical pharmacogene involved in the metabolism of~
20% of commonly used drugs across a broad spectrum of medical disciplines including …

Objectives: To provide advice and guidance regarding the management of mood disorders,
derived from scientific evidence and supplemented by expert clinical consensus to formulate …

Translating CYP 2D6 genotype to metabolizer phenotype is not standardized across clinical
laboratories offering pharmacogenetic (PGx) testing and PGx clinical practice guidelines …

Many studies have shown that the efficacy and risk of side effects of drug treatment is
influenced by genetic variants. Evidence based guidelines are essential for implementing …

The implementation of pharmacogenomic (PGx) testing in psychiatry remains modest, in part
due to divergent perceptions of the quality and completeness of the evidence base and …

The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly
polymorphic human CYP2D6 gene locus. CYP2D6 genetic variation impacts the metabolism …

In 2009, the Clinical Pharmacogenetics Implementation Consortium (CPIC, www. cpicpgx.
org), a shared project between Pharmacogenomics Knowledge Base (PharmGKB …

Atomoxetine is a nonstimulant medication used to treat attention‐deficit/hyperactivity
disorder (ADHD). Cytochrome P450 (CYP) 2D6 polymorphisms influence the metabolism of …

Both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch
Pharmacogenetics Working Group provide therapeutic recommendations for well‐known …